Literature DB >> 15240739

The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501.

Nicole Kerlero de Rosbo1, Joel F Kaye, Miriam Eisenstein, Itzhack Mendel, Romana Hoeftberger, Hans Lassmann, Roni Milo, Avraham Ben-Nun.   

Abstract

Autoimmune response to the myelin-associated oligodendrocytic basic protein (MOBP), a CNS-specific myelin constituent, was recently suggested to play a role in the pathogenesis of multiple sclerosis (MS). The pathogenic autoimmune response to MOBP and the associated pathology in the CNS have not yet been fully investigated. In this study, we have characterized the clinical manifestations, pathology, T cell epitope-specificity, and TCRs associated with experimental autoimmune encephalomyelitis (EAE) induced in SJL/J mice with recombinant mouse MOBP (long isoform, 170 aa). Analysis of encephalitogenic MOBP-reactive T cells for reactivity to overlapping MOBP peptides defined MOBP15-36 as their major immunodominant epitope. Accordingly, MOBP15-36 was demonstrated to be the major encephalitogenic MOBP epitope for SJL/J mice, inducing severe/chronic clinical EAE associated with intense perivascular and parenchymal infiltrations, widespread demyelination, axonal loss, and remarkable optic neuritis. Molecular modeling of the interaction of I-A(s) with MOBP15-36, together with analysis of the MOBP15-36-specific T cell response to truncated peptides, suggests MOBP20-28 as the core sequence for I-A(s)-restricted recognition of the encephalitogenic region MOBP15-36. Although highly focused in their epitope specificity, the encephalitogenic MOBP-reactive T cells displayed a widespread usage of TCR Vbeta genes. These results would therefore favor epitope-directed, rather than TCR-targeted, approaches to therapy of MOBP-associated pathogenic autoimmunity. Localization by molecular modeling of a potential HLA-DRB1*1501-associated MOBP epitope within the encephalitogenic MOBP15-36 sequence suggests the potential relevance of T cell reactivity against MOBP15-36 to MS. The reactivity to MOBP15-36 detected in MS shown here and in another study further emphasizes the potential significance of this epitope for MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240739     DOI: 10.4049/jimmunol.173.2.1426

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis.

Authors:  Bernadette Pöllinger
Journal:  J Mol Med (Berl)       Date:  2012-01-10       Impact factor: 4.599

Review 2.  The immunopathophysiology of multiple sclerosis.

Authors:  Gregory F Wu; Enrique Alvarez
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

3.  MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects.

Authors:  Samantha Jilek; Myriam Schluep; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Neurol Sci       Date:  2012-06-30       Impact factor: 3.307

Review 4.  Activation pathways that drive CD4+ T cells to break tolerance in autoimmune diseases.

Authors:  Sai Harsha Krovi; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2022-02-10       Impact factor: 10.983

5.  Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized" Multiple Sclerosis-like Disease.

Authors:  Nathali Kaushansky; Miriam Eisenstein; Sigalit Boura-Halfon; Bjarke Endel Hansen; Claus Henrik Nielsen; Ron Milo; Gabriel Zeilig; Hans Lassmann; Daniel M Altmann; Avraham Ben-Nun
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

Review 6.  Alcohol and multiple sclerosis: an immune system-based review.

Authors:  Maryam Fahim; Aryan Rafiee Zadeh; Pouria Shoureshi; Keyvan Ghadimi; Masoumeh Cheshmavar; Neda Sheikhinia; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-04-15

7.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240

8.  DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).

Authors:  Nathali Kaushansky; Daniel M Altmann; Chella S David; Hans Lassmann; Avraham Ben-Nun
Journal:  J Neuroinflammation       Date:  2012-02-08       Impact factor: 8.322

Review 9.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

Review 10.  DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele.

Authors:  Nathali Kaushansky; Avraham Ben-Nun
Journal:  Front Oncol       Date:  2014-10-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.